AIM ImmunoTech (NYSE:AIM) Shares Down 5.7% – Should You Sell?

Posted by Darlene League on Jan 2nd, 2025

AIM ImmunoTech Inc. (NYSE:AIM – Get Free Report)’s stock price traded down 5.7% during trading on Tuesday . The company traded as low as $0.19 and last traded at $0.20. 915,238 shares traded hands during mid-day trading, an increase of 198% from the average session volume of 307,402 shares. The stock had previously closed at $0.21.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Maxim Group decreased their target price on shares of AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating for the company in a research report on Tuesday, October 22nd. Ascendiant Capital Markets reduced their price target on AIM ImmunoTech from $5.00 to $4.50 and set a “buy” rating for the company in a research report on Tuesday, December 10th.

View Our Latest Stock Analysis on AIM

AIM ImmunoTech Stock Up 8.2 %

The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $13.66 million, a P/E ratio of -0.46 and a beta of -0.36. The firm has a 50-day moving average price of $0.22 and a two-hundred day moving average price of $0.29.

Institutional Investors Weigh In On AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC acquired a new position in shares of AIM ImmunoTech Inc. (NYSE:AIM – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech at the end of the most recent quarter. Institutional investors and hedge funds own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

(Get Free Report)

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).